Medigen Vaccine Biologics Balance Sheet Health
Financial Health criteria checks 6/6
Medigen Vaccine Biologics has a total shareholder equity of NT$3.9B and total debt of NT$23.0M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are NT$4.3B and NT$456.9M respectively.
Key information
0.6%
Debt to equity ratio
NT$23.05m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$1.76b |
| Equity | NT$3.86b |
| Total liabilities | NT$456.88m |
| Total assets | NT$4.32b |
Financial Position Analysis
Short Term Liabilities: 6547's short term assets (NT$2.5B) exceed its short term liabilities (NT$199.9M).
Long Term Liabilities: 6547's short term assets (NT$2.5B) exceed its long term liabilities (NT$257.0M).
Debt to Equity History and Analysis
Debt Level: 6547 has more cash than its total debt.
Reducing Debt: 6547's debt to equity ratio has reduced from 37.5% to 0.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6547 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6547 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 1.3% each year